Abstract
The screening and characterization of cancer stem cells (CSCs) has been challenging due to sample scarcity. We have developed a miniaturized high-content screening (HCS) assay platform to study intra-cellular proteins related to the survival and apoptosis of CSCs with chemotherapeutic treatment. By overcoming critical bottlenecks associated with sample scarcity, we are able to elucidate the drug responses of the side-population (SP) phenotype characteristics of CSCs. This successful miniaturization of HCS assays facilitates the development of cancer drug treatments, and paves the way for nanoliter volume manipulation for cell-based studies and screening.
| Original language | English |
|---|---|
| Pages (from-to) | 29-34 |
| Number of pages | 6 |
| Journal | Nano Today |
| Volume | 7 |
| Issue number | 1 |
| DOIs | |
| State | Published - Feb 2012 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Cancer stem cells
- Drug resistance
- High-content screening
ASJC Scopus subject areas
- Biotechnology
- Bioengineering
- Biomedical Engineering
- General Materials Science
- Pharmaceutical Science
Fingerprint
Dive into the research topics of 'Elucidating drug resistance properties in scarce cancer stem cells using droplet microarray'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver